The National Cancer Institute (NCI), part of the National Institutes of Health, awarded a $400,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Promilead, LLC, a company located in Columbia, South Carolina. The grant titled "Activating TFEB to Enhance the Efficacy of Immunotherapy for Triple Negative Breast Cancer" aims to develop a novel small-molecule compound, USCYL01, that activates the TFEB protein to boost the anti-tumor immune response and improve the efficacy of immune checkpoint inhibitor (ICI) and chemotherapy treatments for triple negative breast cancer (TNBC). The project will evaluate the toxicity, pharmacokinetics, and in vivo efficacy of USCYL01 in enhancing ICI plus chemotherapy regimens for TNBC treatment. Successful completion of these Phase I studies will establish the feasibility of developing this TFEB activator as an add-on therapy to unleash the full potential of ICI and chemotherapy combinations for TNBC patients.
Generated 3/4/25, 8:37 AM